射频消融术联合吉非替尼治疗晚期肺腺癌的疗效评价

结核病与肺部健康杂志 ›› 2013, Vol. 2 ›› Issue (1): 11-13.

射频消融术联合吉非替尼治疗晚期肺腺癌的疗效评价

王志鸿，李鲁，林毅，邵壮，宋小勇，周君君

100101 北京,解放军第三O六医院心胸外科(王志鸿现在100853 北京,解放军军医进修学院就读在职研究生)

收稿日期:2013-04-05 出版日期:2013-03-30 发布日期:2013-03-30
通信作者: 李鲁,Email:lilu 306@yahoo.com.cn

Therapeutic evaluation for radiofrequency ablation (RFA) combination with gefitinib for advanced lung adenocarcinoma

WANG Zhi-hong^*, LI Lu, LIN Yi, SHAO Zhuang,SONG Xiao-yong, ZHOU Jun-jun

Department of Cardiothoracic Surgery, No.306 Hospital of PLA, Beijing 100101, China (^*Graduate student, now in:Chinese PLA Postgraduate Medical School, Beijing 100853, China)

Received:2013-04-05 Online:2013-03-30 Published:2013-03-30
Contact: LI Lu, Email:lilu_306@yahoo.com.cn

摘要/Abstract

摘要： 目的观察射频消融(RFA)术联合吉非替尼对晚期肺腺癌的临床效果。方法36例晚期肺腺癌(ⅢA、Ⅳ期)患者采取RFA联合吉非替尼治疗(简称“联合治疗组”),与33例晚期肺腺癌(ⅢA、Ⅳ期)患者单独使用RFA治疗的对照组(简称“对照组”)进行比较。两组间疗效与生活质量评分的比较采用χ²检验,P<0.05为差异有统计学意义。结果根据疗效、生活质量评分等指标进行评价,联合治疗组有效率为66.7%(24/36),高于对照组的30.3%(10/33), 两组之间差异有统计学意义(χ²=9.07,P<0.05)。对接受治疗的患者进行生活质量评价,结果表明联合治疗组中有75.0%(27/36)的患者生活质量良好,而对照组中只有48.5%(16/33)的患者生活质量良好,两组之间差异有统计学意义(χ²=5.24,P<0.05)。两组患者不良反应主要是疼痛、发热、腹泻等,只需对症处理。结论RFA联合吉非替尼综合治疗晚期肺腺癌的方案优于单纯采用RFA的治疗方案。

Abstract: Objective To observe the clinical efficacy of cluster electrode radiofrequency ablation (RFA) combination with gefitinib for advanced lung adenocarcinoma.Methods Thirty-six patients with advanced lung adenocarcinoma of stage ⅢA and stage Ⅳ were treated with RFA and gefitinib combination therapy(referred to as the “treatment group”), while 33 patients were treated with only RFA(referred to as the “group”) as control. The efficacy, life quality and side effect of both groups were compared using χ² test.Results The response rate of combination therapy group was 66.7%(24/36), which is higher than that of RFA therapy group, with 30.3%(10/33) (χ²=9.07,P<0.05). There were 75.0%(24/36)patients of combination therapy group who had good quality of life, while in RFA therapy group, the proportion was 48.5%(16/33)(χ²=5.24,P<0.05). The side effects of patients were pain, diarrhea and fever.Conclusion The RFA and gefitinib combination therapy can improve the therapeutic efficacy in patients with advanced lung adenocarcinoma.

王志鸿，李鲁，林毅，邵壮，宋小勇，周君君. 射频消融术联合吉非替尼治疗晚期肺腺癌的疗效评价[J]. 结核病与肺部健康杂志, 2013, 2(1): 11-13.

WANG Zhi-hong^*, LI Lu, LIN Yi, SHAO Zhuang,SONG Xiao-yong, ZHOU Jun-jun. Therapeutic evaluation for radiofrequency ablation (RFA) combination with gefitinib for advanced lung adenocarcinoma[J]. Journal of Tuberculosis and Lung Health, 2013, 2(1): 11-13.